메뉴 건너뛰기




Volumn 70, Issue 4, 2009, Pages 509-517

Effectiveness and tolerability of oral ziprasidone in psychiatric inpatients with an acute exacerbation of schizophrenia or schizoaffective disorder: A multicenter, prospective, and naturalistic study

Author keywords

[No Author keywords available]

Indexed keywords

ZIPRASIDONE;

EID: 66349117036     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: 10.4088/JCP.08m04410     Document Type: Article
Times cited : (5)

References (56)
  • 2
    • 0035029416 scopus 로고    scopus 로고
    • Short-term inpatient pharmacotherapy of schizophrenia
    • Osser DN, Sigadel R. Short-term inpatient pharmacotherapy of schizophrenia. Harv Rev Psychiatry 2001;9:89-104 (Pubitemid 32372934)
    • (2001) Harvard Review of Psychiatry , vol.9 , Issue.3 , pp. 89-104
    • Osser, D.N.1    Sigadel, R.2
  • 3
    • 33746855617 scopus 로고    scopus 로고
    • The Expert Consensus Guidelines: Treatment of Behavioral Emergencies 2005
    • Allen MA, Currier GW, Carpenter D, et al. The Expert Consensus Guidelines: Treatment of Behavioral Emergencies 2005. J Psychiatr Pract 2005;11(suppl 1):1-108
    • (2005) J Psychiatr Pract , Issue.11 SUPPL. 1 , pp. 1-108
    • Allen, M.A.1    Currier, G.W.2    Carpenter, D.3
  • 4
    • 34447321275 scopus 로고    scopus 로고
    • Ziprasidone for schizophrenia and bipolar disorder: A review of the clinical trials
    • DOI 10.1111/j.1527-3458.2007.00008.x
    • Greenberg WM, Citrome L. Ziprasidone for schizophrenia and bipolar disorder: a review of the clinical trials. CNS Drug Rev 2007;13:137-177 (Pubitemid 47052346)
    • (2007) CNS Drug Reviews , vol.13 , Issue.2 , pp. 137-177
    • Greenberg, W.M.1    Citrome, L.2
  • 5
    • 0035012418 scopus 로고    scopus 로고
    • Intramuscular (IM) ziprasidone 20 mg is effective in reducing acute agitation associated with psychosis: A double-blind, randomized trial
    • DOI 10.1007/s002130000658
    • Daniel DG, Potkin SG, Reeves KR, et al. Intramuscular (IM) ziprasidone 20 mg is effective in reducing acute agitation associated with psychosis: a double-blind, randomized trial. Psychopharmacology (Berl) 2001;155:128-134 (Pubitemid 32417820)
    • (2001) Psychopharmacology , vol.155 , Issue.2 , pp. 128-134
    • Daniel, D.G.1    Potkin, S.G.2    Reeves, K.R.3    Swift, R.H.4    Harrigan, E.P.5
  • 6
    • 7844224760 scopus 로고    scopus 로고
    • Ziprasidone 40 and 120 mg/day in the acute exacerbation of schizophrenia and schizoaffective disorder: A 4-week placebo-controlled trial
    • DOI 10.1007/s002130050755
    • Keck P Jr, Buffenstein A, Ferguson J, et al. Ziprasidone 40 and 120 mg/day in the acute exacerbation of schizophrenia and schizoaffective disorder: a 4-week placebo-controlled trial. Psychopharmacology (Berl) 1998;140:173-184 (Pubitemid 28538477)
    • (1998) Psychopharmacology , vol.140 , Issue.2 , pp. 173-184
    • Keck Jr., P.1    Buffenstein, A.2    Ferguson, J.3    Feighner, J.4    Jaffe, W.5    Harrigan, E.P.6    Morrissey, M.R.7
  • 7
    • 0033136622 scopus 로고    scopus 로고
    • Ziprasidone 80 mg/day and 160 mg/day in the acute exacerbation of schizophrenia and schizoaffective disorder: A 6-week placebo-controlled trial
    • and the Ziprasidone Study Group
    • Daniel DG, Zimbroff DL, Potkin SG, et al., and the Ziprasidone Study Group. Ziprasidone 80 mg/day and 160 mg/day in the acute exacerbation of schizophrenia and schizoaffective disorder: a 6-week placebo-controlled trial. Neuropsychopharmacology 1999;20:491-505
    • (1999) Neuropsychopharmacology , vol.20 , pp. 491-505
    • Daniel, D.G.1    Zimbroff, D.L.2    Potkin, S.G.3
  • 9
    • 0038653525 scopus 로고    scopus 로고
    • A meta-analysis of the efficacy of second-generation antipsychotics
    • DOI 10.1001/archpsyc.60.6.553
    • Davis JM, Chen N, Glick ID. A meta-analysis of the efficacy of second-generation antipsychotics. Arch Gen Psychiatry 2003;60:553-564 (Pubitemid 36682312)
    • (2003) Archives of General Psychiatry , vol.60 , Issue.6 , pp. 553-564
    • Davis, J.M.1    Chen, N.2    Glick, I.D.3
  • 10
    • 13744256171 scopus 로고    scopus 로고
    • Efficacy and tolerability of ziprasidone versus risperidone in patients with acute exacerbation of schizophrenia or schizoaffective disorder: An 8-week, double-blind, multicenter trial
    • Addington DEN, Pantelis C, Dineen M, et al. Efficacy and tolerability of ziprasidone versus risperidone in patients with acute exacerbation of schizophrenia or schizoaffective disorder: an 8-week, double-blind, multicenter trial. J Clin Psychiatry 2004;65:1624-1633
    • (2004) J Clin Psychiatry , vol.65 , pp. 1624-1633
    • Addington, D.E.N.1    Pantelis, C.2    Dineen, M.3
  • 11
    • 4744338410 scopus 로고    scopus 로고
    • Randomized, controlled, double-blind multicenter comparison, of the efficacy and tolerability of ziprasidone and olanzapine in acutely III inpatients with schizophrenia or schizoaffective disorder
    • DOI 10.1176/appi.ajp.161.10.1837
    • Simpson GM, Glick ID, Weiden PJ, et al. Randomized, controlled, double-blind multicenter comparison of the efficacy and tolerability of ziprasidone and olanzapine in acutely ill inpatients with schizophrenia or schizoaffective disorder. Am J Psychiatry 2004;161:1837-1847 (Pubitemid 39314678)
    • (2004) American Journal of Psychiatry , vol.161 , Issue.10 , pp. 1837-1847
    • Simpson, G.M.1    Glick, I.D.2    Weiden, P.J.3    Romano, S.J.4    Siu, C.O.5
  • 12
    • 34948813543 scopus 로고    scopus 로고
    • Comparison of ziprasidone and aripiprazole in acutely ill patients with schizophrenia or schizoaffective disorder: A randomized, double-blind, 4-week study
    • DOI 10.1097/YIC.0b013e32816f7779, PII 0000485020071100000007
    • Zimbroff D, Warrington L, Loebel A, et al. Comparison of ziprasidone and aripiprazole in acutely ill patients with schizophrenia or schizoaffective disorder: a randomized, double-blind, 4-week study. Int Clin Psychopharmacol 2007;22:363-370 (Pubitemid 47530841)
    • (2007) International Clinical Psychopharmacology , vol.22 , Issue.6 , pp. 363-370
    • Zimbroff, D.1    Warrington, L.2    Loebel, A.3    Yang, R.4    Siu, C.5
  • 14
    • 33646681652 scopus 로고    scopus 로고
    • A 24-week randomized study of olanzapine versus ziprasidone in the treatment of schizophrenia or schizoaffective disorder in patients with prominent depressive symptoms
    • DOI 10.1097/01.jcp.0000204137.82298.06, PII 0000471420060400000008
    • Kinon BJ, Lipkovich I, Edwards SB, et al. A 24-week randomized study of olanzapine versus ziprasidone in the treatment of schizophrenia or schizoaffective disorder in patients with prominent depressive symptoms. J Clin Psychopharmacol 2006;26:157-162 (Pubitemid 43740339)
    • (2006) Journal of Clinical Psychopharmacology , vol.26 , Issue.2 , pp. 157-162
    • Kinon, B.J.1    Lipkovich, I.2    Edwards, S.B.3    Adams, D.H.4    Ascher-Svanum, H.5    Siris, S.G.6
  • 15
    • 25144456112 scopus 로고    scopus 로고
    • Effectiveness of antipsychotic drugs in patients with chronic schizophrenia
    • for the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Investigators
    • Lieberman JA, Stroup TS, McEvoy JP, et al., for the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Investigators. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 2005;353:1209-1223
    • (2005) N Engl J Med , vol.353 , pp. 1209-1223
    • Lieberman, J.A.1    Stroup, T.S.2    McEvoy, J.P.3
  • 17
    • 1342328623 scopus 로고    scopus 로고
    • Tolerability of ziprasidone: An expanding perspective
    • Daniel DG. Tolerability of ziprasidone: an expanding perspective. J Clin Psychiatry 2003;64(suppl 19):40-49
    • (2003) J Clin Psychiatry , vol.64 , Issue.SUPPL. 19 , pp. 40-49
    • Daniel, D.G.1
  • 18
    • 84921432808 scopus 로고    scopus 로고
    • Ziprasidone for schizophrenia and severe mental illness
    • Cochrane Review. CD001945
    • Bagnall A, Lewis RA, Leitner ML. Ziprasidone for schizophrenia and severe mental illness (Cochrane Review). Cochrane Database Syst Rev 2000;(4):CD001945
    • (2000) Cochrane Database Syst Rev , Issue.4
    • Bagnall, A.1    Lewis, R.A.2    Leitner, M.L.3
  • 20
    • 40549118840 scopus 로고    scopus 로고
    • Long-term changes in weight and plasma lipids during maintenance treatment with ziprasidone
    • Weiden PJ, Newcomer JW, Loebel AD, et al. Long-term changes in weight and plasma lipids during maintenance treatment with ziprasidone. Neuropsychopharmacology 2008;33:985-994
    • (2008) Neuropsychopharmacology , vol.33 , pp. 985-994
    • Weiden, P.J.1    Newcomer, J.W.2    Loebel, A.D.3
  • 21
    • 34047173462 scopus 로고    scopus 로고
    • A 6-month prospective, observational, naturalistic, uncontrolled study to evaluate the effectiveness and tolerability of oral ziprasidone in patients with schizophrenia
    • on behalf of the ZIS Study Group
    • Arango C, Gomez-Beneyto M, Brenlla J, et al, on behalf of the ZIS Study Group. A 6-month prospective, observational, naturalistic, uncontrolled study to evaluate the effectiveness and tolerability of oral ziprasidone in patients with schizophrenia. Eur Neuropsychopharmacol 2007;17:456-463
    • (2007) Eur Neuropsychopharmacol , vol.17 , pp. 456-463
    • Arango, C.1    Gomez-Beneyto, M.2    Brenlla, J.3
  • 22
    • 34548137741 scopus 로고    scopus 로고
    • Effectiveness, safety, and tolerability of ziprasidone for treating schizophrenia patients undergoing usual care: A 12-month, open-label, flexible-dose, naturalistic observational trial
    • DOI 10.1016/j.pnpbp.2007.06.008, PII S0278584607001996
    • Ratner Y, Gibel A, Yorkov V, et al. Effectiveness, safety, and tolerability of ziprasidone for treating schizophrenia patients undergoing usual care: a 12-month, open-label, flexible-dose, naturalistic observational trial. Prog Neuropsychopharmacol Biol Psychiatry 2007;31:1401-1409 (Pubitemid 47302551)
    • (2007) Progress in Neuro-Psychopharmacology and Biological Psychiatry , vol.31 , Issue.7 , pp. 1401-1409
    • Ratner, Y.1    Gibel, A.2    Yorkov, V.3    Ritsner, M.S.4
  • 23
    • 0003248994 scopus 로고    scopus 로고
    • Expanding the frontier of treatment research
    • published online Mar 21, 1999. ArtID1a. doi: 10.1037/1522-3736.2.1.21a
    • Norquist G, Lebowitz B, Hyman S. Expanding the frontier of treatment research [published online Mar 21, 1999]. Prev Treatment 1999;2(1):ArtID1a. doi: 10.1037/1522-3736.2.1.21a
    • (1999) Prev Treatment , vol.2 , Issue.1
    • Norquist, G.1    Lebowitz, B.2    Hyman, S.3
  • 24
    • 0002278232 scopus 로고    scopus 로고
    • Expert Consensus Guideline Series: Treatment of Schizophrenia 1999
    • Expert Consensus Guideline Series: Treatment of Schizophrenia 1999. J Clin Psychiatry 1999;60(suppl 11):1-80
    • (1999) J Clin Psychiatry , vol.60 , Issue.SUPPL. 11 , pp. 1-80
  • 25
    • 0032923291 scopus 로고    scopus 로고
    • Treatment research at the crossroads: The scientific interface of clinical trials and effectiveness research
    • Wells KB. Treatment research at the crossroads: the scientific interface of clinical trials and effectiveness research. Am J Psychiatry 1999;156:5-10 (Pubitemid 29034873)
    • (1999) American Journal of Psychiatry , vol.156 , Issue.1 , pp. 5-10
    • Wells, K.B.1
  • 26
    • 0033987870 scopus 로고    scopus 로고
    • Characteristics of participants and nonparticipants in medication trials for treatment of schizophrenia
    • Woods SW, Ziedonis DM, Sernyak MJ, et al. Characteristics of participants and nonparticipants in medication trials for treatment of schizophrenia. Psychiatr Serv 2000;51:79-84 (Pubitemid 30036753)
    • (2000) Psychiatric Services , vol.51 , Issue.1 , pp. 79-84
    • Woods, S.W.1    Ziedonis, D.M.2    Sernyak, M.J.3    Diaz, E.4    Rosenheck, R.A.5
  • 31
    • 66349107022 scopus 로고    scopus 로고
    • Outcome measurement from research to clinical practice
    • IsHak WW, Burt T, Sederer LI, eds. Washington, DC: American Psychiatric Publishing Inc
    • Dickey B. Outcome measurement from research to clinical practice. In: IsHak WW, Burt T, Sederer LI, eds. Outcome Measurement in Psychiatry: A Critical Review. Washington, DC: American Psychiatric Publishing Inc; 2002:15-22
    • (2002) Outcome Measurement in Psychiatry: A Critical Review , pp. 15-22
    • Dickey, B.1
  • 32
    • 0036695527 scopus 로고    scopus 로고
    • The 2 "Es" of research: Efficacy and effectiveness trials
    • Streiner DL. The 2 "Es" of research: efficacy and effectiveness trials. Can J Psychiatry 2002;47:552-556
    • (2002) Can J Psychiatry , vol.47 , pp. 552-556
    • Streiner, D.L.1
  • 33
    • 0000503515 scopus 로고
    • The Brief Psychiatric Rating Scale
    • Overall JE, Gorham DR. The Brief Psychiatric Rating Scale. Psychol Rep 1962;10:799-812
    • (1962) Psychol Rep , vol.10 , pp. 799-812
    • Overall, J.E.1    Gorham, D.R.2
  • 34
    • 0003412410 scopus 로고
    • US Dept Health, Education, and Welfare publication (ADM) No 76-338. Rockville, Md: National Institute of Mental Health
    • Guy W. ECDEU Assessment Manual for Psychopharmacology-Revised. US Dept Health, Education, and Welfare publication (ADM) No 76-338. Rockville, Md: National Institute of Mental Health; 1976:157-165
    • (1976) ECDEU Assessment Manual for Psychopharmacology-Revised , pp. 157-165
    • Guy, W.1
  • 35
    • 0003412410 scopus 로고
    • US Dept Health, Education, and Welfare publication (ADM) No 76-338. Rockville, Md: National Institute of Mental Health
    • Guy W. ECDEU Assessment Manual for Psychopharmacology-Revised. US Dept Health, Education, and Welfare publication (ADM) No 76-338. Rockville, Md: National Institute of Mental Health; 1976:218-222
    • (1976) ECDEU Assessment Manual for Psychopharmacology-Revised , pp. 218-222
    • Guy, W.1
  • 36
    • 0020535524 scopus 로고
    • A self-report scale predictive of drug compliance in schizophrenics: Reliability and discriminative validity
    • Hogan TP, Awad AG, Eastwood R. A self-report scale predictive of drug compliance in schizophrenics: reliability and discriminative validity. Psychol Med 1983;13:177-183 (Pubitemid 13132147)
    • (1983) Psychological Medicine , vol.13 , Issue.1 , pp. 177-183
    • Hogan, T.P.1    Awad, A.G.2    Eastwood, R.3
  • 37
    • 0034804963 scopus 로고    scopus 로고
    • El Cuestionario de Actitud hacia la Medicación (Drug Attitude Inventory: DAI-30) en población española
    • Garcia I, Hormaechea JA, Arango C, et al. El Cuestionario de Actitud hacia la Medicación (Drug Attitude Inventory: DAI-30) en población española. Arch Psiquiatr 2001;64;261-272
    • (2001) Arch Psiquiatr , vol.64 , pp. 261-272
    • Garcia, I.1    Hormaechea, J.A.2    Arango, C.3
  • 39
    • 33645051491 scopus 로고    scopus 로고
    • Clinical trials for antipsychotic drugs: Design conventions, dilemmas, and innovations
    • Stroup TS, Alves WM, Hamer RM, et al. Clinical trials for antipsychotic drugs: design conventions, dilemmas, and innovations. Nat Rev Drug Discov 2006;5:133-146
    • (2006) Nat Rev Drug Discov , vol.5 , pp. 133-146
    • Stroup, T.S.1    Alves, W.M.2    Hamer, R.M.3
  • 40
    • 0024638447 scopus 로고
    • Effect sizes for interpreting changes in health status
    • Kazis LE, Anderson JJ, Meenan RF. Effect sizes for interpreting changes in health status. Med Care 1989;27:S178-S189
    • (1989) Med Care , vol.27
    • Kazis, L.E.1    Anderson, J.J.2    Meenan, R.F.3
  • 41
    • 0036788207 scopus 로고    scopus 로고
    • Insight into illness and attitudes toward medications among inpatients with schizophrenia
    • Sajatovic M, Rosch DS, Sivec HJ, et al. Insight into illness and attitudes toward medications among inpatients with schizophrenia. Psychiatr Serv 2002;53:1319-1321
    • (2002) Psychiatr Serv , vol.53 , pp. 1319-1321
    • Sajatovic, M.1    Rosch, D.S.2    Sivec, H.J.3
  • 42
    • 0037212062 scopus 로고    scopus 로고
    • Safety of olanzapine versus conventional antipsychotics in the treatment of patients with acute schizophrenia: A naturalistic study
    • for the EUROPA Study Group
    • Alvarez E, Bobes J, Gomez JC, et al, for the EUROPA Study Group. Safety of olanzapine versus conventional antipsychotics in the treatment of patients with acute schizophrenia: a naturalistic study. Eur Neuropsychopharmacol 2003;13:39-48
    • (2003) Eur Neuropsychopharmacol , vol.13 , pp. 39-48
    • Alvarez, E.1    Bobes, J.2    Gomez, J.C.3
  • 43
    • 33847768125 scopus 로고    scopus 로고
    • Tolerability and effectiveness of quetiapine in inpatients with schizophrenia: Results from the acute phase of the TESIS study
    • Abstract
    • Perez V, Cañas F, Tafalla M, et al. Tolerability and effectiveness of quetiapine in inpatients with schizophrenia: results from the acute phase of the TESIS study [Abstract]. Eur Neuropsychopharmacol 2005;15(suppl 3):S493
    • (2005) Eur Neuropsychopharmacol , vol.15 , Issue.SUPPL. 3
    • Perez, V.1    Cañas, F.2    Tafalla, M.3
  • 44
    • 33645846052 scopus 로고    scopus 로고
    • Effect of initial ziprasidone dose on treatment persistence in schizophrenia
    • Mullins CD, Shaya FT, Zito JM, et al. Effect of initial ziprasidone dose on treatment persistence in schizophrenia. Schizophr Res 2006;83:277-284
    • (2006) Schizophr Res , vol.83 , pp. 277-284
    • Mullins, C.D.1    Shaya, F.T.2    Zito, J.M.3
  • 45
    • 33947729686 scopus 로고    scopus 로고
    • Effectiveness, tolerability, and safety of ziprasidone in patients with schizophrenia or schizoaffective disorder: Results of a multi-centre observational trial
    • DOI 10.1016/j.eurpsy.2006.06.004, PII S0924933806001325
    • Kudla D, Lambert M, Domin S, et al. Effectiveness, tolerability, and safety of ziprasidone in patients with schizophrenia or schizoaffective disorder: results of a multi-centre observational trial. Eur Psychiatry 2007;22:195-202 (Pubitemid 46507733)
    • (2007) European Psychiatry , vol.22 , Issue.3 , pp. 195-202
    • Kudla, D.1    Lambert, M.2    Domin, S.3    Kasper, S.4    Naber, D.5
  • 47
    • 34548847495 scopus 로고    scopus 로고
    • The "Seroquel" Outcomes Study (SOS): Efficacy and tolerability of quetiapine in a long-term, naturalistic study of patients with schizophrenia
    • for the SOS GROUP
    • Gibert J, Giner J, Bobes J, et al, for the SOS GROUP. The "Seroquel" Outcomes Study (SOS): efficacy and tolerability of quetiapine in a long-term, naturalistic study of patients with schizophrenia. Int J Psychiatry Clin Pract 2007;11:222-232
    • (2007) Int J Psychiatry Clin Pract , vol.11 , pp. 222-232
    • Gibert, J.1    Giner, J.2    Bobes, J.3
  • 48
    • 0036735166 scopus 로고    scopus 로고
    • Optimal dosing of atypical antipsychotics in adults: A review of the current evidence
    • Citrome L, Volavka J. Optimal dosing of atypical antipsychotics in adults: a review of the current evidence. Harv Rev Psychiatry 2002;10:280-291
    • (2002) Harv Rev Psychiatry , vol.10 , pp. 280-291
    • Citrome, L.1    Volavka, J.2
  • 49
    • 0035015262 scopus 로고    scopus 로고
    • Dose selection and comparator drugs in schizophrenia research
    • Kane JM. Dose selection and comparator drugs in schizophrenia research. J Clin Psychiatry 2001;62(suppl 9):29-32 (Pubitemid 32452718)
    • (2001) Journal of Clinical Psychiatry , vol.62 , Issue.SUPPL. 9 , pp. 29-34
    • Kane, J.M.1
  • 50
    • 1542776092 scopus 로고    scopus 로고
    • The Expert Consensus Guideline Series: Optimizing Pharmacologic Treatment of Psychotic Disorders: Introduction: methods, commentary, and summary
    • Kane JM, Leucht S, Carpenter D, et al. The Expert Consensus Guideline Series: Optimizing Pharmacologic Treatment of Psychotic Disorders: Introduction: methods, commentary, and summary. J Clin Psychiatry 2003;64(suppl 12):5-19
    • (2003) J Clin Psychiatry , vol.64 , Issue.SUPPL. 12 , pp. 5-19
    • Kane, J.M.1    Leucht, S.2    Carpenter, D.3
  • 53
    • 38549180032 scopus 로고    scopus 로고
    • Correlations of attitudes toward antipsychotic drugs with insight and objective psychopathology in schizophrenia
    • Rocca P, Crivelli B, Marino F, et al. Correlations of attitudes toward antipsychotic drugs with insight and objective psychopathology in schizophrenia. Compr Psychiatry 2008;49:170-176
    • (2008) Compr Psychiatry , vol.49 , pp. 170-176
    • Rocca, P.1    Crivelli, B.2    Marino, F.3
  • 54
    • 35649028046 scopus 로고    scopus 로고
    • Correlates and long-term consequences of poor insight in patients with schizophrenia. a systematic review
    • DOI 10.1093/schbul/sbm002
    • Lincoln TM, Lullmann E, Rief W. Correlates and long-term consequences of poor insight in patients with schizophrenia: a systematic review. Schizophr Bull 2007;33:1324-1342 (Pubitemid 350022767)
    • (2007) Schizophrenia Bulletin , vol.33 , Issue.6 , pp. 1324-1342
    • Lincoln, T.M.1    Lullmann, E.2    Rief, W.3
  • 56
    • 44849131431 scopus 로고    scopus 로고
    • The effect of food on the absorption of oral ziprasidone
    • Miceli JJ, Glue P, Alderman J, et al. The effect of food on the absorption of oral ziprasidone. Psychopharmacol Bull 2007;40:58-68
    • (2007) Psychopharmacol Bull , vol.40 , pp. 58-68
    • Miceli, J.J.1    Glue, P.2    Alderman, J.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.